YIH
CKPT

Y-Intercept (HK)’s Checkpoint Therapeutics CKPT Stock Holding History

Y-Intercept (HK)’s Portfolio CKPT Stock Details CKPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,197
Closed -$35K – 676
2021
Q2 		$35K Buy
+1,197
New +$33.2K 0.01% 571

Other funds holding CKPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SAG
Spotlight Asset Group Oakbrook Terrace, Illinois $143M AUM 20.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
EL
EMFO LLC Weston, Florida $112M AUM 18.79% 1-Year Est. Return

Y-Intercept (HK)'s CKPT Position: Q3 2021 in Review

Y-Intercept (HK) sold out of Checkpoint Therapeutics (CKPT) in Q3 2021, closing a stake of 1,197 shares — an estimated $35K sold.

Y-Intercept (HK) first reported a position in CKPT in Q2 2021 and held it in 1 quarter. The position peaked at $35K in Q2 2021. 67 funds tracked by Wall St. Rank hold CKPT as of Q3 2021.

  • Y-Intercept (HK) reported no remaining Checkpoint Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Y-Intercept (HK) sold 1,197 Checkpoint Therapeutics shares in Q3 2021, an estimated $35K.
  • Y-Intercept (HK) first reported a position in Checkpoint Therapeutics in Q2 2021 and held it in 1 quarter.
  • Y-Intercept (HK)'s Checkpoint Therapeutics position peaked at $35K in Q2 2021.
  • 67 funds tracked by Wall St. Rank held Checkpoint Therapeutics as of Q3 2021.

Based on Y-Intercept (HK)'s 13F filing for Q3 2021, filed 15 Nov 2021.